Cadbury owner Mondelez stockpiling chocolates in case of no-deal Brexit
Companies are putting together contingency plans should they not be able to move their goods freely around Europe post-Brexit
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1076 stories · page 8 of 11
AstraZeneca’s severe asthma treatment granted breakthrough therapy designation
A breakthrough therapy designation is designed to expedite the development and review of medicines that are intended to treat a serious and have shown promise in early-stage clinical trials
AstraZeneca’s lupus drug falls at final hurdle
Only one new lupus treatment has been approved in the last 60 years, so today’s news won’t come as a surprise to many scientists and doctors
AstraZeneca’s new diabetes autoinjector pen approved by European regulators
“Today's approval of Bydureon BCise will enable us to offer an additional treatment option for patients with type-2 diabetes whose blood sugar levels are inadequately controlled by other glucose-lowering medicines together with diet and exe
AstraZeneca valuation 'too stretched', says Jefferies as it downgrades the stock
Jefferies cut its rating on AstraZeneca to ‘hold’ from ‘buy’ but raised its target price to 6,200p from 5,942p
JPMorgan Cazenove gives AstraZeneca shares a boost, hiking its target price to 6,500p from 5,800p
JPMorgan’s analysts said the target hike comes after their updated their numbers to make “further upgrades to new launch trajectories, and include risk-adjusted forecasts for three further pipeline shots on goal”
Archive
Cineworld investors hope World Cup and hot weather failed to keep customers away in first-half
The day ahead sees Cineworld and Legal & General report their first-half results
Archive
HSBC will ring down the curtain on the bank's interim reporting season, but other financials also in focus
Aside from HSBC's numbers, Prudential, L&G, Standard Life Aberdeen, and Hargreaves Lansdown are all on the results docket in the coming week
Veltyco slides as it forecasts half-year earnings miss
A look at some of the biggest risers and fallers in London on Thursday
AstraZeneca plots a return to growth as cancer portfolio boosts first-half performance
The drugs giant's oncology division grew revenues by 42%
FTSE 100 keeps head above water at close: Facebook in focus
The Nasdaq on Wall Street is down over 88 points at the time of writing, at 7,420.
Archive
Blue-chip deluge on Thursday with Royal Dutch Shell, AstraZeneca and Diageo (and more) set to report
Three of the 10 largest London-listed companies (by capitalisation) are updating the market on Thursday. A dozen or more other household names are also expected to report.
AstraZeneca sells European rights to heart drug
It will receive an initial US$200mln followed by a further US$10mln, plus sales-related milestone payments
Archive
Apres moi le deluge: Flood of blue chip results to dominate in coming week, including BT Group
Over the five sessions in the Week Ahead, around 20% of the FTSE 100 index will report results or issue a trading update, with about half that number due on Thursday alone
Investments and investor services
FTSE 100: Forget Brexit, here’s what we’ll learn from a bumper earnings week
We have a deluge of earnings statements from some of Britain's biggest businesses. Below we discuss the themes likely to emerge from the mid-term reporting season
Redx Pharma looks for some Porcupine help in its fight against cancer and fibrosis
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
Concepta appoints former CEO of Genedrive as new chairman
The AIM-listed fertility aid manufacturer said Matthew Walls would become chairman with immediate effect, while former chair Adam Reynolds would become a non-executive director
Two of AstraZeneca’s key cancer drugs win speedy approvals in Japan
Lynparza and Imfinzi are likely to play an important role if AstraZeneca is to hit its target of generating annual sales of US$45bn by 2023
AstraZeneca’s Lynparza drug sails through late-stage ovarian cancer study
The drug has already been approved for later use in ovarian and breast cancer patients, but the SOLO-1 trial has sowed it could be useful as a first-line treatment
UBS reckons Tagrisso will be worth more than US$5bn a year to AstraZeneca by 2022
Tagrisso sales look like they will beat expectations over the coming years, but UBS has concerns that the future profits drag brought about by externalisation deals hasn’t been properly factored into estimates yet
AstraZeneca’s pipeline turnaround is “remarkable”, but potential is already priced in
Liberum’s Roger Franklin likes AstraZeneca, but thinks the current share price is fair, given the potential of the pipeline
AstraZeneca and Eli Lilly halt late-stage Alzheimer’s study as drug shows no sign of working
AstraZeneca and Lilly’s lanabecestat drug can be added to the list of failed Alzheimer’s treatments; in fact, 99% of all drugs developed to treat the disease have failed clinical trials in the past ten years
Avacta Group appoints Immunocore’s Eliot Forster as non-executive chairman
The AIM-listed firm said Dr Trevor Nichols, who has acted as chairman of the board since January 2014, will remain on the board as non-executive director
AstraZeneca and Merck present data from prostate cancer trial at ASCO 2018
The data showed that the combination of Lynparza and abiraterone can help patients with a specific form of prostate cancer to live for longer without their disease getting worse
AstraZeneca chalks up another phase III fail as COPD drug misses target
Chief medical officer Dr Sean Bohen called the result disappointing
AstraZeneca receives more solid data for its Imfinzi lung cancer treatment
Imfinzi showed a “statically-significant” benefit to overall survival in patients with unresectable stage III non-small cell lung cancer
Third time lucky for AstraZeneca and its Lokelma hyperkalaemia treatment
The US Food and Drug Administration had twice rejected AstraZeneca’s applications for Lokelma due to issues at the manufacturing plant in Texas
Investments and investor services
FTSE 100 propelled to new record close as pound weakens and Dow Jones breaches 25,000
FTSE 100 reached a new record close on Monday after achieving it last time on Thursday
AstraZeneca disappoints with Q1 sales but ‘remains on track’ to hit full-year growth guidance
The FTSE 100-drugs giant expects product sales, which have been in decline for a while now, to return to growth this year
FTSE 100 closes lower, off record peak; Glencore top loser
Footsie closed around nine points at 7,778 but it was still up 0.70% on the week - its eighth weekly gain in a row.
Archive
It’s all about the drugs: AstraZeneca Q1 results will be Friday’s main focus
The day ahead includes first-quarter numbers from both blue-chip drugmaker AstraZeneca PLC and mid-cap generics firm Hikma Pharmaceuticals PLC
FTSE 100 closes in red as there is little around to spark investor interest
FTSE 250 fared better though closing ahead by around 15 points at 20,800.
Archive
Wide variety of blue-chip updates due in coming week - from Centrica to AstraZeneca
Week ahead includes updates from drugs giant AstraZeneca, mobile phones operator Vodafone Group, British Gas-owner Centrica, and postal delivery firm Royal Mail Group
AstraZeneca suffers clinical setback
Its drug targeting people with chronic obstructive pulmonary disease failed to make a statistically meaningful difference
AstraZeneca sells off rights to Seroquel for US$538mln
The FTSE 100 drugmaker has been selling off non-core assets in recent years as it narrows its focus on three primary areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory
Redx Pharma shares soar 69% as executive chairman increases stake
The drug developer said following this acquisition, Iain Ross will hold 600,000 ordinary shares in the company, representing 0.47% of the issued share capital
Proactive news snapshot: Redx Pharma, Tissue Regenix, SDX Energy …
A glance at some of the day's highlights from the Proactive Investors newswire
Tern shares spike up as holding company extends security capability for Microsoft’s internet of things platform
A look at some of the biggest risers and fallers in London on Tuesday
Circassia Pharmaceuticals upbeat as AstraZeneca increases stake
Steve Harris, Circassia’s chief executive, said he expected to see strong revenue growth in 2018
AstraZeneca shares under pressure after lung cancer setback
AZ’s Imfinzi was paired with tremelimumab, an immune checkpoint blocker, to treat patients with non-small cell lung cancer
Redx Pharma shares soar 48% after it recruits heavy hitter from drugs major AstraZeneca
Chairman Iain Ross will step back into a non-executive role following the appointment
FTSE 100 extends gains in the final sessions
Stocks consolidated gains at the death with bid stock Shire the best performing blue-chip
US FDA approves AstraZenca’s Tagrisso drug as first-line treatment for lung cancer
Tagrisso will now be the first treatment doctors use on lung cancer patients whose tumours have a specific mutation called an EFGR mutation
AstraZeneca and GlaxoSmithKline share price targets tweaked and on Jefferies' 'buy' ahead of Q1 results season for the druggies
The broker is still enamoured of the UK big hitters but doesn't expect it to be plain sailing for either
Shares of Compugen gain on US$200mln licensing deal for cancer treatments
Isreali drugmaker will get a US$10mln upfront payment from MedImmune in the deal
US and European regulators accept AstraZeneca's cancer drug applications
The US FDA has accepted AstraZeneca’s biologics licence application for Moxetumomab Pasudotox while the European Medicines Agency will review the company's marketing authorisation application for Lynparza
Jefferies upgrades AstraZeneca rating to ‘buy’ from ‘hold’ as it believes drugmaker “is at a turning point”
The US broker also raised its target price for the FTSE 100-listed firm to 5,600p, up from 5,075p previously, with the shares trading at 4,865p in mid-morning trading
Investments and investor services
FTSE 100 closes nearly 1.7% lower as Brexit deal strengthens sterling
FTSE 100 closed down 121 points at 7,042, joining other European benchmarks, which saw red
AstraZeneca pushes back timeline for MYSTIC phase III lung cancer clinical trial
Based on current predictions, the final analysis of overall survival data from the phase III study is expected in the second-half of the year rather than the first
Investments and investor services
Kin slumps as share suspension looms, elsewhere another ‘shell’ soars after getting deals done
A look at some of today's top risers and fallers in London
Investments and investor services
FTSE 100 closes up, boosted by mining stocks and as pound strengthens against the dollar
The UK's blue-chip index closes up 20.84 points to 7,234.81
Investments and investor services
RELX and ConvaTec among the names in Thursday’s diary
RELX is expected to see revenue and profit growth, whereas ConvaTec will report on what's seen as a disappointing year.
Archive
Inflation numbers from UK and US to be eyed closely in coming week amid rate hike fears
Week ahead includes the latest UK and US consumer price indexes, plus corporate updates from RELX PLC, Coca Cola HBC PLC, Shire PLC and ConvaTec PLC
AstraZeneca: Trump tax bump can't disguise the challenge it and other druggies face
AZ is one of a number of UK companies with significant US operations to update on the benefits of cutting the corporate tax rate to 21% from 35%
FTSE 100 slides as dollar rallies on expectations of a March rate hike by the Fed
US workers' pay increased 2.9% year-on-year, compared to expectations of a 2.6% increase.
Archive
Day ahead: BT and AstraZeneca quarterly earnings, US non-farm payrolls
The day ahead includes quarterly earnings from BT and AstraZeneca as well as the US non-farm payrolls report
FTSE 100 ends lower as pound firms; housebuilders weigh
Britain's top tier index closed around 54 points lower at 7,533
FTSE 100 closes higher, just, with miners in support
The FTSE 100, dragged higher by the miners, got off to a strong start today, but closed juts about six points higher
Archive
Unilever among the quality blue chip updates scheduled, but Fed meeting and US jobs data more important
Week ahead includes updates from FTSE 100 AstraZeneca PLC, BT Group PLC, Royal Dutch Shell PLC, and Unilever PLC, plus a Federal Reserve meeting and January US jobs data
AstraZeneca reports positive top-line data from phase III COPD trial
The KRONOS trial showed that Astra’s PT010 inhaler can improve lung function in patients with moderate to severe chronic obstructive pulmonary disease
New York's BIO CEO & Investor conference brings biotech investors, companies and analysts together
Now in its 20th year, the conference brings investors, analysts, and management of companies together
Investments and investor services
FTSE 100 closes in the red as sterling booms
“If he intended it, Treasury Secretary Steven Mnuchin has done a first class job of whacking the dollar,” declared Neil Wilson at ETX Capital. .
AstraZeneca gets approval for two cancer and asthma treatments in Japan
Lynparza has been approved for use as a maintenance therapy in ovarian cancer patients, while Fasenra has been cleared as an add-on treatment for severe asthma sufferers
Circassia and AstraZeneca to widen scope of COPD inhaler after post-launch trial success
AstraZeneca intends to file for the trial data to be included to widen the marketing label for Turdoza
AstraZeneca submits supplemental new drug application for Tagrisso in Japan
The new drug application follows positive phase II trial results
AstraZeneca shares up 1.2% after getting regulatory green light for asthma drug
The US Food & Drug Administration gave the thumbs up overnight
AstraZeneca lifts full-year core earnings guidance
Full-year earnings will still be in a bit of a Soriot-state, but won't decline as much as previously expected
FTSE 100 firmly in red as EU cuts growth forecasts for UK
After a bullish run over the past few months, European and US markets endured a rare off day on Thursday
Archive
AstraZeneca's results: focus will be on the pipeline and recovery options for the MYSTIC trial
Will Astra get into the MYSTIC? The company said not all hope was lost for its lung cancer trial, which flunked in the summer
Archive
M&S and Sainsbury's take centre stage as BoE interest rate hike excitement dies down
The week ahead includes earnings from M&S, Sainsbury's, ABF, Direct Line, Wetherspoon and AstraZeneca while macro-economic announcements will be thin on the ground
AstraZeneca’s severe asthma treatment fails in late-stage study but FDA approval of rare blood cancer drug boosts shares
Investors were more interested in Tuesday evening’s news that the US FDA had approved Calquence as a treatment for people with mantle cell lymphoma
AstraZeneca edges higher after double dose of updates on cancer and diabetes drugs
A new formulation of Astra’s diabetes drug has been given the green light by the FDA, while it has submitted a second NDA in Japan for its Lynparza cancer drug, this time for use in breast cancer
AstraZeneca’s breast cancer drug given priority review by FDA
A priority review means regulators will come to a conclusion earlier than usual and Astra expects to hear back in the first quarter of 2018
AstraZeneca’s Imfinzi cancer drug clears another regulatory hurdle
The US Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) for the treatment of certain lung cancer patients.
AstraZeneca rises as Credit Suisse praises recent progress, hikes price target by £10
CS analysts say AstraZeneca is finally starting to get over the patent expiries of several blockbuster drugs, including Crestor, Seroquel and Nexium
Koovs jumps on partnership deal with online clothing retailer N Brown
A look at some of the biggest risers and fallers today in London
FTSE 100 closes in negative territory despite resource stock gains
The UK blue chip index closed at 7,526, well below the session peak of 7,557.00 and close to the day’s low of 7,531.48
AstraZeneca continues to face pricing pressures and competitive headwinds, says ShoreCap
ShoreCap cut its price target to 4,600p from 5,154p on AstraZeneca and left its rating at ‘hold’.
AstraZeneca’s Tagrisso lung cancer drug granted ‘breakthrough therapy designation’ by US FDA
"The Breakthrough Therapy Designation acknowledges not only Tagrisso's potential as a 1st-line standard of care in advanced EGFR mutation-positive NSCLC, but also the significant need for improved clinical outcomes in this disease”
SynairGen to target COPD with inhaled interferon beta treatment
"A COPD programme is now both highly attractive and economically viable"
Exane BNP Paribas swoons over AstraZeneca’s drugs pipeline as it upgrades to 'outperform'
The pipeline isn’t a pipe dream any more, so say Exane analysts
Bernstein ups stance on AstraZeneca to ‘outperform’, citing big pipeline, takeover possibilities
Bernstein’s analyst said they consider AstraZeneca as a “pipeline-driven, return-to-growth story”, pointing that the group has one of the fullest phase 3 trial pipelines
AstraZeneca offloads remaining rights to anaesthetic portfolio to Aspen for US$766mln
“Disposing the remaining rights to the medicines allows both companies to benefit from greater efficiencies as AstraZeneca continues to focus our resources on our three main therapy areas”
Shire, AstraZeneca and GSK in the red as JP Morgan looks at risks facing pharmaceutical sector
Shire remains the "standout stock" as it has an "extremely compelling valuation”, according to JP Morgan
Teva Pharmaceutical names Danish industry veteran Kare Schultz as its new chief executive
The new chief executive joins Teva - the world's biggest seller of generics medicines - from Denmark's H. Lundbeck A/S, where he has been president and CEO since May 2015
AstraZeneca lung cancer trial results impress but risks remain, analysts say
Analysts see the results of phase III trials for Imfinzi and Tagrisso as a positive development for AstraZeneca but have raised concerns about other areas of the business
AstraZeneca gains after reporting positive results from two trials of lung cancer treatments
AstraZeneca is making progress in trials of its lung cancer treatments
FTSE 100 closes almost 36pts up as traders buy back in
The blue chip index closed out almost 36 points higher at 7,413
FTSE 100 trims losses
The FTSE 100 retreated as investors worry about Hurricane Irma, while mixed economic statistics raised fresh concerns over the UK economy.
Celgene says US FDA places holds on clinical trials for cancer checkpoint inhibitor being developed with AstraZeneca
Celegene said the FDA's decision was due to risks seen in other trials for another checkpoint inhibitor, Merck & Co.'s anti-PD-1 antibody pembrolizumab, in combination with immunomodulatory agents
Natixis upgrades AstraZeneca to ‘buy’ on prospect of positive results from key MYSTIC lung cancer trial
The Natixis analysts said: “We expect successful results for MYSTIC, which prompts our target of 5,738p, up from 5,000p previously, but still giving over 25% upside potential”
FTSE 100 closes lower as traders continue to fret about North Korea
FTSE 100 closed down 18.79 at 7,354, while the FTSE 250 lost over 74 points at 19,652.
AstraZeneca gets regulatory green light for breast cancer drug
Faslodex can now be deployed as a single therapy following regulatory sign off
Champions Oncology hooks up with AstraZeneca to work on characterising tumour models
The collaboration will help Astra develop further therapeutic approaches for patients
AstraZeneca ovarian cancer drug approved for wider use
Lynparza was initially approved to be given to women with advanced ovarian cancer who had stopped responding to three rounds of chemotherapy
FTSE 100 plunges on North Korea fears
The FTSE 100 finished 108 points lower at 7,390, about 13 points above its intra-day low
AstraZeneca scores much-needed clinical success
It has been granted a priority review by the US Food & Drug Administration for acalabrutinib, which has been developed to treat a rare form of non-Hodgkin’s lymphoma
AstraZeneca on the front foot after US FDA speeds up process for Imfinzi lung cancer drug
AstraZeneca is making progress on its lung cancer drug Imfinzi but suffered a set back on its Mystic treatment
AstraZeneca's share price slump on Mystic trial unwarranted, says investor Neil Woodford
AstraZeneca has maintained that its Mystic lung cancer treatment could be positive on improving overall survival rates after a failed trial
Merck & Co cuts full year profit guidance; agrees drug collaboration with AstraZeneca
Merck & Co is yet to determine the full impact of the ‘Petya’ cyber attack in June that disrupted operations